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Elevated blood levels of S100B in schizophrenia have so far been mainly attributed to glial pathology, as S100B is produced by
astro- and oligodendroglial cells and is thought to act as a neurotrophic factor with eﬀects on synaptogenesis, dopaminergic and
glutamatergic neutrotransmission. However, adipocytes are another important source of S100B since the concentration of S100B
in adipose tissue is as high as in nervous tissue. Insulin is downregulating S100B in adipocytes, astrocyte cultures and rat brain. As
reviewed in this paper, our recent studies suggest that overweight, visceral obesity, and peripheral/cerebral insulin resistance may
be pivotal for at least part of the elevated S100B serum levels in schizophrenia. In the context of this recently identiﬁed framework
of metabolic disturbances accompanying S100B elevation in schizophrenia, it rather has to be attributed to systemic alterations in
glucose metabolism than to be considered a surrogate marker for astrocyte-speciﬁc pathologies.
1.Signiﬁcanceof S100BasSurrogateMarker
for Glial or Blood-Brain Barrier Dysfunction
inSchizophrenia
S100B is a secretory protein which is implicated in various
intracellular and extracellular functional processes. Previous
studies have indicated its involvement in the regulation of
proteinphosphorylation,cytoskeletonassembly,Ca2+ home-
ostasis, transcription factors, and glucose metabolism [1].
BloodlevelsofS100Blevelsareincreasedinschizophrenia,as
summarized in a recent meta-analysis of 13 studies involving
420 patients with schizophrenia and 393 control subjects [2].
Serum S100B reaches high eﬀect sizes in schizophrenia com-
pared to controls (mean ± SD: 2.02 ± 1.78), as conﬁrmed
by including only studies investigating drug-free patients
(mean ± SD: 1.94 ± 1.33; n = 7). Elevated S100B levels
wereassociatedwithacuteexacerbationsordeﬁcitsymptoms
and have frequently been attributed to glial damage and
dysfunction or blood-brain barrier leakage [2–5]. S100B is
produced by astrocytes and oligodendrocytes and is acting
as a neurotrophic factor with eﬀects on synaptogenesis,
dopaminergic and glutamatergic neutrotransmission [6–9].
Whitaker-Azmitia et al. observed a loss of dendrites in mice
overexpressing S100B [10]. Interestingly, schizophrenia is
indeed associated with certain haplotypes, leading to an
increased S100B expression [11], and postmortem studies
are suggestive of a progressive reduction of neuropil [12].
Therefore, a causal link between the aforementioned ﬁnding
of elevated S100B levels and schizophrenia might be consid-
ered.
A recent analysis of cerebrospinal ﬂuid (CSF) from
ﬁrst onset schizophrenia cases observed increased levels of
S100B, without indications for impaired glial or neuronal
cell integrity, as assessed by simultaneous measurement of
non-secretory glial and neuronal proteins (glial ﬁbrillary
acidic protein/GFAP, myelin basic protein/MBP, neuron
speciﬁc enolase/NSE) [13]. This ﬁnding speaks against the
assumption of glial damage during acute psychosis, but2 Cardiovascular Psychiatry and Neurology
could be interpreted as indirect evidence for an activated
glial synthesis and release of S100B during acute psychosis.
Of note, S100B has also been detected outside the nervous
system, for example, in adipose and chondroid tissues,
lymphocytes, melanocytes, the myocardium, and vascular
endothelial/smooth muscle cells [8].
In conclusion, previous ﬁndings support the hypothesis
that S100B is involved in the pathogenesis of schizophrenia,
but elevated levels of this protein may not exclusively reﬂect
brain- or glial-speciﬁc pathologies. Recently, Marchi et al.
suggested that serum S100B is an ideal marker of blood-
brain barrier integrity, because with a molecular weight of
21kDa(S100Bdimer)itmaynotpenetratethroughanintact
blood-brain barrier [14]. Furthermore, its concentration is
high in central nervous system ﬂuids and low in blood.
Indeed, serum levels of S100B were directly correlated with
an experimental opening of the blood-brain barrier [14–16].
However, unlike in patients suﬀering from stroke, traumatic
brain injury, or inﬂammatory brain disorders, there is no
clear experimental evidence for a disruption of the blood-
brain barrier in schizophrenia. Therefore, it remains unclear
if serum levels of S100B are reﬂecting blood-brain barrier
integrity also in schizophrenia.
2. Altered Peripheral and CerebralGlucose
Metabolism inSchizophrenia
Recent studies indicate novel interpretations of previous
S100B ﬁndings in the context of disturbances in energy
metabolism in schizophrenia (see below). Therefore, this
section is brieﬂy summarizing current knowledge on
schizophrenia-related alterations in glucose metabolism.
Schizophrenia is characterized by a 20% higher mortality
rate compared with the general population. Important
contributing factors are an increased risk for type 2 diabetes
and metabolic syndrome (deﬁned by the American Heart
Association as presence of three or more of the components:
abdominal obesity, atherogenic dyslipidemia, elevated blood
pressure, insulin resistance, prothrombotic state, and proin-
ﬂammatory state). Weight gain and impaired glucose toler-
ance have been mainly attributed to side eﬀects of atypical
antipsychotic medication, such as clozapine and olanzapine
[17–19]. However, impaired fasting glucose tolerance has
also been reported in drug na¨ ıve schizophrenia cases [20–
25]a n du n a ﬀected siblings [26], suggesting disease-inherent
abnormalities in peripheral glucose metabolism.
Cerebral insulin signaling seems to be likewise aﬀected
in schizophrenia [27, 28], probably causing disturbances
in neural glucose uptake and utilization, as revealed by
measurementsofelevatedCSFglucoselevels[29],invivoﬂu-
orodeoxyglucosepositronemissiontomography(FDG-PET)
and functional magnetic resonance imaging (fMRI) studies
[30–32]. State-dependent alterations in cerebral glucose-
metabolism and functional disconnection have been found
in brain regions which are involved in the pathophysiology
of schizophrenia (e.g., of the prefrontal cortex, thalamus
and mediotemporal lobe). The mediotemporal region and
the hippocampus in particular appear to be of speciﬁc
importance for cognitive impairment in schizophrenia.
Studies addressing neuronal activation using fMRI have
demonstrated that schizophrenic subjects show impaired
patternsofhippocampalactivityinnoveltydetection,declar-
ative learning, and memory tasks [33–35]. Notably, it has
been demonstrated that hippocampus-dependent memory
performance can be improved by the administration of
g l u c o s ei nr o d e n t sa n dh u m a n s[ 36, 37]. In humans it has
been shown that this eﬀect is more pronounced when the
task is cognitively demanding [37], or when the cognitive
resources that can be applied for it are sparse, as is the
case in the elderly and in schizophrenia patients [38, 39].
Of note, low rodent insulin-like growth factor 1 (IGF-
1) concentrations were associated with impaired glucose
metabolism in brain areas involved in learning and memory
[40]. In schizophrenic subjects, clozapine has been shown
to normalize disease-related IGF-1 deﬁcits [41–43], and
glucose administration boosts mediotemporal as well as
dorsolateralprefrontalneuronalactivityduringtheencoding
into declarative memory [44, 45].
3. Adipose Tissueas aPotentialSource of S100B
AdipocytesappeartobeanimportantsourceofserumS100B
since the concentration of S100B in adipose tissue is as high
as in nervous tissue [46–49]. This fact has been barely con-
sidered during the past years. Remarkably, S100B is closely
linked to the regulation of cellular energy metabolism. An
immunoelectron-microscopic study suggested that S100B
may be involved in the regulation of lipolysis [50]. The
release of S100B from adipocytes is reduced by insulin,
and activated by physiological factors such as stress (cat-
echolamines and adrenocorticotropic hormone (ACTH))
or fasting [51–53]. Interestingly, a study on streptotocin-
induced diabetes in Sprague-Dawley rats revealed a 2-fold
increase in S100B protein levels in both brain and white
fat tissue [54]. Therefore, an increased adipose tissue mass
or changes of insulin metabolism such as insulin resistance
most probably play a major role in increased S100B levels in
schizophrenia too, given the increased prevalence of obesity
and metabolic syndrome in patients and their ﬁrst-degree
relatives (see above) [55, 56].
4. S100B SerumIs Correlatedwith
Body MassIndexandA-FABPin
Healthy HumanSubjects
Indeed, a recent study showed a close correlation between
body mass index (BMI) and serum S100B levels [57]. This
study assessed S100B serum levels in 60 adult subjects (36
female, 24 male, age 22–58 years) with a BMI between
18–45kg/m2 without a prior history of neuropsychiatric
disorders. S100B levels correlated with the BMI (r = 0.538,
P<. 001), levels of leptin (r = 0.683, P<. 001), and
adipocyte-type fatty acid-binding protein (A-FABP; r =
0.801, P<. 001) (Figure 1(a)). Accordingly, follow-up single
group comparisons of BMI groups showed that S100B levels
in obesity were signiﬁcantly higher than in overweight (P =Cardiovascular Psychiatry and Neurology 3
.006, Cohen’s d = 2.25), and normal weight subjects (P =
.001, Cohen’s d = 2.90), or in overweight higher than in
the latter (P = .049, Cohen’s d = 0.65) (Figure 1(b)).
A stepwise regression analysis showed that of the variables
age, leptin, and A-FABP only the latter was signiﬁcantly
predicting S100B (P<. 001). Correspondingly, new evidence
from population studies and experimental animal models
indicates that serum A-FABP is a powerful new risk marker
for predicting metabolic syndrome and arteriosclerosis
[58].
Eﬀect sizes as measured by Cohen’s d (see upper
paragraph) indicated medium (0.5 <d<0.8) to strong
eﬀects (0.9 <d ) of BMI on S100B blood levels. This ﬁnding
may explain previous reports indicating a direct relationship
between S100B blood levels with body weight in anorexia
nervosa: Eﬀect sizes that were obtained from data given
for anorexic subjects by Ehrlich et al. [59]b e f o r ea n da f t e r
weight gain (i.e., mean ± SD of BMI: initially 14.5 ± 1.3,
after >10% weight gain 17.1 ± 0.9; mean ± SD of S100B
levels: initially 0.095 ± 0.041μg/l, ﬁnally: 0.128 ± 0.063μg/l)
and by Holtkamp et al. [60]a f t e r2 1w e e k so fw e i g h tg a i n
(mean ± SD of BMI: initially 14.8 ± 1.3, ﬁnally 17.0 ±
1.2; mean ± SD of S100B levels: initially 0.077 ± 0.023μg/l,
ﬁnally 0.107 ± 0.035μg/l) were 0.81 and 1.3, respectively. In
conclusion, S100B blood levels are directly related to BMI
across an extensive range of nutritional states spanning from
starvation to extreme obesity. Importantly, the eﬀect sizes
thatBMIexertsonS100Bbloodlevelsinneuropsychiatrically
healthy subjects (obesity compared to overweight: Cohen’s
d = 2.25; obesity compared to normal weight: Cohen’s d =
2.90) are well within the range of eﬀect sizes observed in
schizophrenia (all studies: 2.02 ± 1.78; studies with drug-
free patients: 1.94 ± 1.33) [2]. In conclusion, the correlation
of S100B levels with other adipose-related measures, such as
leptin and A-FABP, indicates that BMI or waist-to-hip ratio
adjustments are strongly advised for future clinical studies
examining peripheral blood S100B levels in order to avoid
misinterpretation of results.
5.Elevated S100B Levels in Schizophrenia Are
Presumably Associated with Visceral Obesity
andInsulinResistance
A recent study thus assessed S100B in both medicated and
drug free schizophrenic patients along with the BMI, mea-
sures of glucose utilization and adipokine levels [61]. The
subjectswerecomprisedof26inpatientswithacuteparanoid
schizophrenia and 32 control subjects, which did not diﬀer
signiﬁcantly regarding age, gender, BMI and smoking habits
(Table 1). Eleven patients were unmedicated for at least 6
weeks before admission (Table 2); 15 were already put on
atypical antipsychotics (amisulpride, aripiprazole, clozapine,
olanzapine, quetiapine, risperidone, or ziprasidone) for 26
± 21 days, but still suﬀered from acute psychosis. Only
benzodiazepines were allowed as additional psychotropic
medication (for ≤6 days). Blood was collected between
9:00 and 11:00AM (nonfasted). S100B and the follow-
ing adipose-related factors were determined from serum
samples: leptin, monocyte chemotactic protein 1 (MCP-
1), hepatocyte growth factor (HGF), resistin, plasminogen
activator inhibitor 1 (PAI-1), tumor necrosis factor alpha
(TNF-α) and high-sensitivity C-reactive protein (hs-CRP).
Levels of glucose, triglycerides and C-peptide1 were also
assessed.
In control subjects, circulating S100B concentrations
correlated signiﬁcantly with the BMI (r = 0.540, P = .001),
as in the abovementioned study in 60 subjects without a
prior history of neuropsychiatric disorders [57]. Moreover,
adipokines (leptin: r = 0.545, P = .001, HGF: r = 0.441, P =
.012, resistin: r = 0.377, P = .033) and C-peptide/glucose
ratios (an estimate of insulin resistance, r = 0.432, P =
.014) predicted S100B levels. In contrast, circulating S100B
levels in schizophrenia subjects were neither correlated with
the BMI (drug free: r =− 0.108, P = .751; with drug:
r =− 0.007, P = .981) nor with levels of leptin, HGF and
resistin (Figure 2). It has to be clariﬁed by future studies,
if the diﬀerent ﬁnding in schizophrenia may be explained
by a predominant visceral fat distribution, which is not
adequately assessed by the BMI. This idea is supported by
our ﬁnding of MCP-1-correlated S100B levels in the patient
group (r = 0.673, P = .023). MCP-1 is known to be
particularly related to the visceral fat mass [62].
As illustrated in Figure 3 and Table 1,a c u t e l yi l l
schizophrenic subjects showed elevated S100B levels (P =
.012). Indications of insulin resistance were revealed by
increasedglucose(P<. 001),C-peptidelevels(P = .002)and
C-peptide/glucose ratios (P = .006). S100B and BMI were
elevated in medicated schizophrenic patients (P = .041/P <
.001), but controls with a BMI ≥ 25 were also found to
show increased S100B levels (P = .025) and comparable
correlations held true when adipokines were considered as
predictors of S100B levels. A disease speciﬁc increase of
S100B could however be demonstrated for closely BMI-
matched drug free patients (P = .028, Table 2). Similarly,
the ﬁnding of disease-related insulin insensitivity persisted
when controlling for eﬀects of medication, smoking or stress
(ANCOVA).
These results are suggestive of insulin resistance in
schizophrenia that may result in an increased release of
S100B from adipose tissue. Commonly observed weight gain
upon neuroleptic treatment would thus appear on the basis
of an increased metabolic vulnerability in patients due to
primaryinsulinresistance,whichisalsopresentindependent
of medication.
6.Studies on Insulin-Regulated S100B Release
from Adipose TissueAreChallenged by
FindingsinCSFandBrain Tissue
Schizophrenia-related disturbances in S100B expression are
not speciﬁc for adipose tissue, but have also been observed
in CSF and brain tissue (see above) [13, 63, 64]. Given the
general distribution of energy consumption with the brain
having the highest glucose turnover, especially under normal
or resting conditions, a cerebral insulin resistance appears
plausible,asopposedtoadiseasethatprimarilyorexclusively4 Cardiovascular Psychiatry and Neurology
0
0.04
0.08
0.12
0.16
0.2
15 20 25 30 35 40 45
BMI
S
1
0
0
B
(
μ
g
/
L
)
r = 0.538
P <. 001
(a)
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
BMI ≥ 30
(n = 24)
S
1
0
0
B
(
μ
g
/
L
)
BMI < 25
(n = 22)
BMI 25 to 29.9
(n = 14)
P = .006
P = .001
P = .049
(b)
Figure 1: [57]: S100B serum levels were closely correlated with the BMI (a). Obese subjects (BMI ≥ 30) showed signiﬁcantly elevated S100B
levels in comparison to normal weight (BMI < 25) or overweight (BMI 25.0–29.9) subjects (b). Annotation: (a) r = Pearson correlation
coeﬃcient; (b) data are given as mean ± standard deviation (SD).
Table 1: Demographics and clinical measurements of control subjects and patients with paranoid schizophrenia. Annotation: data are given
as mean ± standard deviation (SD), n.a. = not applicable,
aANOVA,
bChi-square-test,
cANCOVA, ↑↓ positive or negative inﬂuence on
measures, bold P-values were signiﬁcant, underlined P-values remained signiﬁcant after Bonferroni correction.
Demographic data Controls
(n = 32)
Paranoid schizophrenia
(n = 26)
P-values
Schizophrenia versus controls
Age [y] 34.4 ± 10.8 34.7 ± 11.3 0.914a
Duration of disease [y]— 8 ± 9 n.a.
Male/Female [n]2 0 /12 17/9 0.820b
BMI [kg/m2] 24.3 ± 3.8 27.7 ± 5.7 0.196a
Smokers/non-smokers [n]1 4 /18 16/10 0.178b
Clinical data/measures Mean ± SD Mean ± SD Inﬂuence of diagnosis
(uncorrected ANOVA)
Inﬂuence of
diagnosis
(ANCOVA)
Inﬂuence of BMI
(ANCOVA)
PANSS total score — 84.8 ±11.2 n.a. n.a. —
PANSS positive score — 20.1 ±4.9 n.a. n.a. —
PANSS negative score — 22.1 ±6.5 n.a. n.a. —
PANSS general score — 42.7 ±5.6 n.a. n.a. —
S100B [μg/L] 0.052 ±0.018 0.072 ±0.038 0.012a ↑ 0.039c ↑ 0.384c
hs-CRP [mg/L] 1.76 ±2.89 3.11 ±2.68 0.073a ↑ 0.510c 0.001c ↑
TNF-α [ng/L] 2.38 ±1.62 3.45 ±2.44 0.052a ↑ 0.193c 0.102c
Leptin [μg/L] 9.62 ±15.25 18.24 ±22.96 0.093a ↑ 0.628c < 0.001c ↑
MCP-1 [ng/L] 285.6 ±155.3 397.0 ±233.3 0.034a ↑ 0.409c < 0.001c ↑
HGF [μg/L] 2.44 ±1.92 3.83 ±3.37 0.054a ↑ 0.488c < 0.001c ↑
Resistin [μg/L] 6.09 ±2.11 6.31 ±1.97 0.681a 0.893c 0.469c
PAI-1 [μg/L] 1.47 ±0.81 2.35 ±1.50 0.006a ↑ 0.046c ↑ 0.048c ↑
Triglycerides [mg/dL] 146.1 ±68.2 221.3 ±160.1 0.020c ↑ 0.088c ↑ 0.124c
Glucose [mg/dL] 82.9 ±18.6 104.3 ±21.6 < 0.001a ↑ < 0.001c ↑ 0.894c
C-peptide [pmol/L] 1907.8±1305.6 2572.8 ±1376.5 < 0.001a ↑ 0.002c ↑ 0.213cCardiovascular Psychiatry and Neurology 5
Table 2: Demographics and clinical measurements of drug free patients with paranoid schizophrenia compared with control subjects which
were closely matched for BMI and smoking habits. Annotation: data are given as mean ± standard deviation (SD), n.a. = not applicable,
aANOVA,
bChi-square-test, ↑↓ positive or negative inﬂuence on measures, bold P-values were signiﬁcant.
Demographic data Controls (n = 11) Paranoid schizophrenia:
drug free (n = 11)
Schizophrenia versus
controls P-values
Age [y]3 4 .7 ±12.03 5 .1 ±13.2 0.947a
Duration of disease [y]— 8 .5 ±10.8—
Male/Female [n]7 /47 /4 1.000b
BMI [kg/m2]2 3 .5 ±3.42 4 .5 ±5.5 0.621a
Smokers/non-smokers [n]6 /57 /4 0.665b
Measures Mean ± SD Mean ± SD
S100B [μg/L] 0.046 ±0.014 0.073 ± 0.033 0.028a ↑
hs-CRP [mg/L] 1.47 ±1.64 2.50 ±2.51 0.267a
TNF-α [ng/L] 2.51 ±1.95 2.95 ±1.79 0.584a
Leptin [μg/L] 11.82 ±16.91 13.74 ± 12.49 0.766a
MCP-1 [ng/L] 314.9 ±190.0 308.8 ± 166.2 0.936a
HGF [μg/L] 2.32 ±1.85 2.84 ±2.11 0.543a
Resistin [μg/L] 5.71 ±1.80 6.70 ±1.83 0.214a
PAI-1 [μg/L] 1.49 ±0.75 2.30 ±1.55 0.139a
Triglycerides [mg/dL] 144.3 ±47.2 205.6 ± 102.3 0.093a ↑
Glucose [mg/dL] 81.1 ±12.2 105.7 ± 25.0 0.011a ↑
C-peptide [pmol/L] 1219.0 ±680.1 2760.3 ±1657.0 0.013a ↑
BMI
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Figure 2: S100B levels in drug free and medicated schizophrenic
patients were not correlated with the BMI. Annotation: r =
correlation coeﬃcient.
aﬀects peripheral adipose tissue [65, 66]. This hypothesis is
in line with observations of a dysfunctional cerebral insulin
receptor signaling in dorsolateral prefrontal cortex tissue
from patients with schizophrenia [27]. Strikingly, insulin has
been shown to downregulate S100B expression in astrocyte
cultures and rat brain [54, 67, 68], in analogy to the above-
mentioned observations in adipose tissue [53, 69]. Previous
cell culture experiments have shown that the expression and
release of S100B from astrocytes and oligodendrocytes is
stimulated by cellular glucose deprivation [6, 70]. A similar
condition may occur in the brains of schizophrenia patients
due to impaired glial glucose uptake as a consequence of
insulin resistance.
Therefore, altered S100B protein expression in schiz-
ophrenia probably indicates systemic disturbances in cellular
energy supply (e.g., by disrupted peripheral and cerebral
insulin signaling) rather than adipocyte- or glia-speciﬁc
pathologies. Upregulated insulin levels might represent a
compensatoryeﬀortcomingupagainsttheseinsulinreceptor
disturbances. Indeed, a better psychopathology proﬁle has
been observed in acutely ill schizophrenic patients with
higher insulin levels, potentially compensating these insulin
receptor disturbances [71]. These considerations are oﬀering
promising new approaches in the therapy of schizophrenia-
related metabolic and psychopathological alterations, for
exampletheusageofglitazones,agroupofinsulinsensitizing
drugs [72, 73].
7.PotentialRelationship of S100B to the
Metabolic Syndrome inSchizophrenia
According to the American Heart Association, the metabolic
syndrome is characterized by a group of cardiovascular risk
factors in one person (http://www.americanheart.org/pre-
senter.jhtml?identiﬁer=4756). They include:6 Cardiovascular Psychiatry and Neurology
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Figure 3: [61]: Elevated S100B serum concentrations (a) and an increased C-peptide/glucose-ratio (b), indicating insulin resistance, were
schizophrenia-related. However, increases of BMI were primarily a consequence of antipsychotic medication (c). Annotation: Data are given
as mean with 95% conﬁdence intervals. Only P-values of signiﬁcant group diﬀerences are displayed.
(i) Abdominal obesity: excessive fat tissue in and around
the abdomen, elevated waist circumference: men—
equal to or greater than 40 inches (102cm);
w o m e n — e q u a lt oo rg r e a t e rt h a n3 5i n c h e s( 8 8c m ) .
(ii) Elevated blood pressure: equal to or greater than
130/85mmHg.
(iii) Insulinresistanceorglucoseintolerance:fastingglucose
e q u a lt oo rg r e a t e rt h a n1 0 0m g / d L .
(iv) Atherogenic dyslipidemia: blood fat disorders—high
triglycerides (greater than 150mg/dL), low HDL
cholesterol (men—less than 40mg/dL; women—
less than 50mg/dL) and high LDL cholesterol—that
foster plaque buildups in artery walls.
(v) Prothrombotic state: e.g., high ﬁbrinogen or PAI-1 in
the blood.
(vi) Proinﬂammatory state: e.g., elevated CRP in the
blood.
Interestingly, we previously observed an upregulation
of the S100B/AGE scavenger sRAGE (soluble receptor of
advanced glycation end products) during reconvalescence
from acute schizophrenia [74]. Beneﬁts of sRAGE have also
beenfoundincardiovascularandmetabolicdisorders,which
are associated with increased AGE levels, such as diabetes
mellitus and arteriosclerosis [75, 76]. A closer look at the
data from our recent study in Molecular Psychiatry reveals
that some of the abovementioned metabolic risk factors were
present in schizophrenia cases, but not all of them were
linked to elevated S100B serum levels (Table 1)[ 61].
(i) Abdominal Obesity: We did not measure waist cir-
cumferences in this study, but blood concentrations
of MCP-1 were elevated in the schizophrenia group
(P = .034), indicating an increased visceral fat mass
[62], and correlating with levels of S100B (r = 0.673,
P = .023).Cardiovascular Psychiatry and Neurology 7
(ii) Elevated Blood Pressure: This was an exclusion crite-
rion of the study. Therefore, the relation of hyperten-
sion to S100B could not be analyzed.
(iii) Insulin Resistance or Glucose Intolerance: Elevated
glucose and C-peptide levels were observed in the
schizophrenia cohort. C-peptide/glucose ratios pre-
dicted S100B levels (r = 0.432, P = .014).
(iv) Atherogenic Dyslipidemia: Triglyceride levels were
slightly elevated in schizophrenic subjects(P = .020),
but were not correlated with S100B concentrations.
HDL and LDL cholesterol were not systematically
assessed.
(v) Prothrombotic State: Schizophrenia cases showed
higher PAI-1 levels (P = .006) that were not
correlated with S100B.
(vi) Proinﬂammatory State: There was a trend towards
elevated hs-CRP and TNF-α levels in schizophrenia.
However, these inﬂammatory parameters were not
related to S100B levels.
It remains unclear whether S100B may be considered
as a predictor of metabolic syndrome in schizophrenia.
This topic has to be elucidated by future studies in drug-
na¨ ıve and prodromal schizophrenia cases with follow-up
blood takes and clinical examinations in larger samples,
comparing diﬀerent standardized treatment regimens. Apart
from the measurement of fasting glucose, triglyceride and
HDL cholesterol levels in patients and controls, it will
be necessary to assess additional clinical parameters such
as blood pressure and waist circumference for a clear
identiﬁcation of patients at risk.
8. Summary and Conclusion
Several studies reported on elevated blood levels of S100B in
schizophrenia, which have been attributed to glial pathology
[2]. However, considerable amounts of S100B are released
from adipose tissue during lipolysis. The release of S100B
from adipocytes is reduced by insulin, and activated by
physiological factors such as stress (catecholamines and
adrenocorticotropic hormone) or fasting [46–48, 51–53].
Our recent observations in healthy human subjects are
suggesting a close relation between serum S100B levels and
the BMI, or levels of the adipose-derived factors leptin,
HGF, resistin and A-FABP [57, 61]. Of note, previous
studies showed that serum A-FABP is a powerful marker for
predicting metabolic syndrome and arteriosclerosis [58].
Given the increased prevalence of visceral obesity and
insulin resistance in schizophrenia, we recently analyzed the
relation of serum S100B levels to the BMI and adipose
derived hormones in acute paranoid schizophrenia [61].
The physiological relation of S100B to the BMI and the
abovementioned adipose-derived factors was disrupted in
schizophrenia. Several reasons may be hypothesized:
(1) Schizophrenia-related disturbances in adipose tissue
distribution, such as increased visceral fat which is
better assessed by the waist-to-hip ratio instead of
BMI. Interestingly, blood concentrations of MCP-
1 were indeed elevated in the schizophrenia group,
indicating an increased visceral fat mass [62], and
correlated with levels of S100B (see above).
(2) Schizophrenia-related disturbances in adipose tissue
metabolism, such as an increased release of S100B,
together with triglycerides and free fatty acids due
to a predisposition to insulin resistance. Indeed,
elevated glucose and C-peptide levels were observed
in the schizophrenia cohort and C-peptide/glucose
ratios predicted S100B levels (see above).
(3) An increased release of S100B from brain tissue, as
suggestedbyhistologicalandCSFstudies[13,63,64].
Notably,insulinhasalsobeenshowntodownregulate
S100B expression in astrocyte cultures and rat brain
[54, 67, 68]. However, an animal study in Wistar
rats suggests that the concentration of S100B may
be diﬀerentially regulated in the periphery and the
centralnervoussystem:lipolysisfollowingfastingwas
linked to an increased release of S100B to serum,
while cerebrospinal ﬂuid levels of S100B were not
signiﬁcantly altered [51]. This topic awaits further
clariﬁcation.
(4) Drug eﬀects on cellular S100B production and
release.
(a) Glial cell culture experiments have shown that
antipsychotic drugs can directly aﬀect glial
S100B release. Increased amounts of S100B
were found in the supernatants of astroglial C6
cells treated with very high doses of risperidone
[77]. In contrary, treatment of astroglial C6 and
oligodendroglial OLN-93 cells with haloperidol
and clozapine at a concentration corresponding
to the assumed therapeutic dose range of these
drugs reduced the release of S100B in vitro
[78]. Other S100B-expressing cell types, like
adipocytes, have not been tested yet in this
context.
(b) Alternatively, the potential inﬂuence of atyp-
ical antipsychotics on S100B via changing
metabolic factors should be considered as a
more indirect mechanism. Among the second-
generation antipsychotics, clozapine and olan-
zapine are associated with the highest risk
of weight gain, as well as changes in insulin
sensitivityandlipidmetabolism,whichincrease
the risk of diabetes and cardiovascular disease
[17–19].
(5) Adrenaline, noradrenalin or ACTH-enhanced release
of S100B from adipose tissue due to a schizophrenia-
relatedactivationoftheendocrinestressaxis[51–53].
This idea is supported by our ﬁnding of free cortisol
index (FCI)
2-correlated S100B levels in untreated
acutely ill patients (unpublished results: r = 0.611,
P = .046).8 Cardiovascular Psychiatry and Neurology
In conclusion, there is evidence for a novel link
between S100B and disturbances of energy metabolism in
schizophrenia, resulting in an increased release of S100B
from brain and adipose tissue. Such systemic alterations in
glucose metabolism may also aﬀect glial S100B release. An
upregulationofS100Bmaybeacompensatoryphenomenon,
increasing intracellular energy supply by activating glycoly-
sis (fructose-1,6-bisphosphate aldolase) and glycogenolysis
(phosphoglucomutase) [79, 80]. Future studies in larger
samples may focus on fasted drug naive schizophrenic sub-
jects and the comparison of diﬀerent standardized treatment
regimens to further elucidate the suggested link between
S100B and abnormal energy metabolism.
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Endnotes
1. C-peptide is generated in the pancreas when proinsulin
is split into insulin and C-peptide. It has no metabolic
function. However, since C-peptide and insulin are
secreted in equimolar amounts, the immunoassay of C-
peptide permits the quantitation of insulin secretion.
Moreover, C-peptide measurement has several advan-
tages over immunoassays of insulin [81]: First of all,
approximately 50% of the portal vein concentration
of insulin is rapidly degraded by the liver whereas
C-peptide extraction by the liver is only about 12%.
As a result, peripheral venous levels of C-peptide
more accurately reﬂect pancreatic insulin secretion
than do peripheral insulin levels. Unlike insulin, which
has signiﬁcant uptake at target tissues, C-peptide is
metabolically fairly inert. It is primarily removed from
the circulation by the kidney, both by degradation and
by urinary excretion. The half-life of C-peptide in the
circulation is between two and ﬁve times longer than
that of insulin. Therefore, C-peptide levels are a more
stable indicator of insulin secretion than the more
rapidly changing insulin levels. A very clear practical
advantage of C-peptide measurement arising from its
relative metabolic inertness as compared to insulin is
that C-peptide levels in peripheral venous blood are
about 5-6 times greater than insulin levels.
2. The FCI is a surrogate marker for free cortisol, which
is the biologically active component. It is calculated
by dividing the serum total cortisol [nmol/L] by the
cortisol-binding globulin (CBG) level [mg/L].
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